Vendor comparison · 2026
Hexarelin vendors: 6 compared on COAs and price
Tissue & recoveryAlso known as Examorelin
Evidence tier
Substantial published literature
312 publications over 32 years · trials not yet curated
- Vendors carrying it
- 6
- 6 with a listed price
- Vendors with checkable COAs
- 1
- 1 publish any certificate
- Lots tested
- 1
- 1 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 21 Nov 2025
- oldest 21 Nov 2025
- Laboratories named
- 1
- most often Freedom Diagnostics Testing
- Median label gap
- 0.0%
- 100% of lots within 5% of label
- Median purity
- 99.08%
- 1 of 1 lots at 99% or above
- Lowest price per mg
- $7.00
- peer median $11.70
- Publications located
- 312
- researched since 1994
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Modern Aminos has the most checkable Hexarelin testing in this index: 1 lot assayed by Freedom Diagnostics Testing, the newest on 21 Nov 2025. The lowest listed price is $7.00 per mg at Good Science Bio, against a peer median of $11.70. 6 vendors carrying Hexarelin are compared below. 1 publish at least one certificate naming a checkable laboratory, 1 lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Hexarelin
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Northline LabsISO/IEC 17025 | 86.195% | $9.00 (77%) | 0 | — | — | — | — | no reportVisit site |
| 2 | Modern AminosISO/IEC 17025COAs need an account | 77.797% | $13.60 (116%) | 1 / 1 | Freedom Diagnostics Testing | 99.1% | 0.0% | ||
| 3 | Good Science Bio | 74.571% | $7.00 (60%) | 0 | — | — | — | — | no reportVisit site |
| 4 | Protide HealthAge-gated COAs | 66.892% | $18.33 (157%) | 0 | — | — | — | — | no reportVisit site |
| 5 | Biotech Peptides | 65.360% | $9.80 (84%) | 0 | — | — | — | — | no reportVisit site |
| 6 | GenX Peptides | 57.669% | $16.50 (141%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Hexarelin is on file. All 1 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
1 of 1 lots at 99% or above; median 99.08%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 1 |
| ≥99.5% | 0 |
100% of lots within 5% of the labelled mass; median gap 0.0%.
| Range | lots |
|---|---|
| ≤2% | 1 |
| 2–5% | 0 |
| 5–10% | 0 |
| 10–20% | 0 |
| >20% | 0 |
6 vendors, $7.00 to $18.33; median $11.70.
| Range | vendors |
|---|---|
| $5.00–$10.00 | 3 |
| $10.00–$15.00 | 1 |
| $15.00–$20.00 | 2 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 1 | 1 | 100% | Public lookup |
Every certificate record
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Report |
|---|---|---|---|---|---|---|---|---|
 Modern Aminos | BX-P-TIC8 | Freedom Diagnostics Testing | 7.5 mg | 7.5 mg | 0.0% | 99.1% | Vendor-published |
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1994 — 32 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
312 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.1% across 1 certificate
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
single lot on record, mean label deviation 0.0%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
6 of 6 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
1 of 1 certificate from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Hexarelin?
A synthetic growth-hormone-releasing hexapeptide studied for growth hormone secretion and cardiovascular effects.
Studied in published research for growth-hormone release and cardiovascular effects.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in animal models and human growth-hormone research. PepIndex does not evaluate clinical significance and does not describe administration.
- The cardiovascular action of hexarelin — Journal of geriatric cardiology : JGC (2014)
Peer-reviewed article indexed in PubMed, published in Journal of geriatric cardiology : JGC (2014).
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway — European journal of medical research (2023)
Peer-reviewed article indexed in PubMed, published in European journal of medical research (2023).
- Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation — Microvascular research (2022)
Peer-reviewed article indexed in PubMed, published in Microvascular research (2022).
- Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases — Endocrine (2015)
Peer-reviewed article indexed in PubMed, published in Endocrine (2015).
- Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury — Drug target insights (2021)
Peer-reviewed article indexed in PubMed, published in Drug target insights (2021).
- Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats — Canadian journal of physiology and pharmacology (2021)
Peer-reviewed article indexed in PubMed, published in Canadian journal of physiology and pharmacology (2021).
- Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy — Die Pharmazie (2019)
Peer-reviewed article indexed in PubMed, published in Die Pharmazie (2019).
- Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice — Peptides (2019)
Peer-reviewed article indexed in PubMed, published in Peptides (2019).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.